U.S. markets closed

Revive Therapeutics Ltd. (RVV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3800-0.0050 (-1.30%)
At close: 3:59PM EST

Revive Therapeutics Ltd.

The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
888 901 0036
http://www.revivethera.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael FrankChairman & CEO377.08kN/A1961
Mr. Carmelo Marrelli CPA, B.Comm., CA, CGA, ACISChief Financial Officer89.11kN/A1971
Dr. Kelly McKee Jr., M.P.H., M.D.Chief Scientific Officer ConsultantN/AN/AN/A
Dr. Onesmo Mpanju Ph.D.Chief Regulatory Affairs ConsultantN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers novel cannabinoid-centric treatments for liver diseases, inflammatory diseases, and skin disorders. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and coronavirus disease; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocybin oral formulations for the treatment of depression, anxiety, etc.; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has a research collaboration agreement with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; and with North Carolina State University for the development of a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Corporate Governance

Revive Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.